Table 3.
The significant KEGG pathway enriched by DEGs.
| Expression | Term | Count | P value | Genes |
|---|---|---|---|---|
| Upregulated | hsa00350: Tyrosine metabolism | 4 | 3.04E-03 | MAOA, AOX1, ADH1B, HPD |
| hsa04270: Vascular smooth muscle contraction | 6 | 3.08E-03 | ACTA2, MRVI1, PLA2G5, KCNMB1, PPP1R14A, MYL9 | |
| hsa00982: Drug metabolism – cytochrome P450 | 4 | 1.91E-02 | FMO2, MAOA, AOX1, ADH1B | |
| hsa04512: ECM-receptor interaction | 4 | 3.62E-02 | LAMA2, ITGB4, SDC4, COL11A1 | |
| Downregulated | hsa04060: Cytokine-cytokine receptor interaction | 8 | 5.53E-04 | LIF, TNFRSF11B, CCL2, TNFSF13B, CCL5, CCL7, TGFB2, IL11 |
| hsa05323: Rheumatoid arthritis | 5 | 2.26E-03 | CCL2, TNFSF13B, CCL5, TGFB2, IL11 | |
| hsa04750: Inflammatory mediator regulation of TRP channels | 5 | 3.34E-03 | PLA2G4A, PLCB4, IGF1, BDKRB1, PLA2G4C | |
| hsa04913: Ovarian steroidogenesis | 4 | 3.62E-03 | PLA2G4A, PTGS2, IGF1, PLA2G4C | |
| hsa05142: Chagas disease (American trypanosomiasis) | 5 | 4.14E-03 | GNA14, CCL2, PLCB4, CCL5, TGFB2 |